Merck Discontinues Certain Cancer Candidate Trials
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.
Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is proving that it’s no different. | In a day that already included discontinuations from Roche and Foghorn Therapeutics,
Merck targets 2025 RSV season
Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...
We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on MRK stock, giving a Buy rating on December 11.Pick the best ...
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...
Shares of Merck & Co. Inc. MRK slipped 1.12% to $100.06 Monday, on what proved to be an all-around mixed trading session for ...
We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), ...
On December 10, JD Health, in collaboration with Merck, a globally renowned biopharmaceutical leader, began offering ...
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback